Skip to main content
Caplight Logo









PureIMS

PureIMS

Private
RodenHealthcare & Life Scienceshttps://pureims.com/

Last Round

Grant

Sep 3, 2025

Total Funding Raised

$4M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

PureIMS is a clinical-stage pharmaceutical and therapeutic devices company that develops and commercializes inhaled therapies based on its proprietary Cyclops® dry powder inhaler platform.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Medical Devices, Drug Discovery

Business Model

B2B

Customer Profile

Revenue Share, Services & Consulting

AI Layer

Non-AI

Keywords

dry powder inhalerDPIinhaled therapydrug delivery platformdrug-device combinationrespiratory drug deliveryinhaler technologypharma licensingclinical-stage pharmamedication systemsdrug repurposingmedtechpulmonary deliverydrug delivery device

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

PureIMS Comparables

Compare PureIMS with similar companies based on industry and business-model similarity.

PureIMS comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Merxin Ltd
83%
Iconovo AB
82%
Hovione
77%

PureIMS Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantSep 3, 2025
VC RoundApr 3, 2023
Early FundingApr 26, 2019
SeedOct 12, 2017

Key People

Founding team and executive leadership

Jaap Wieling

Chief Executive Officer

Executive Team

PureIMS Investors

Notable investors and investment history

PureIMS investors
InvestorRounds
Boost-UP FoundationVC Round
Carduso CapitalVC Round, Early Funding, Seed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 20, 2026

    Open roles increased to 8, 4x the trailing average.

  • Jul 13, 2026

    Open roles increased to 4, representing 33% of headcount.

PureIMS Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

PureIMS Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about PureIMS's valuation, stock price, and market status.

Firmographic Details

HeadquartersRoden
Employee Range11
Year Founded2014
Last FundingSep 3, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?